Prevention of Cognitive Decline in Older Adults With Low Dha/Epa Index in Red Blood Cells

Summary

LO MAPT is an 18-month, phase III, multicenter, randomized, placebo-controlled, 2 parallel groups trial, followed by a 18-month open-label extension phase, to evaluate the efficacy of omega-3 supplementation on cognitive decline in older adults with low DHA/EPA status and subjective memory complaints or family history of Alzheimer disease.

Timeline

Start

2018-04-17

Primary completion

2020-03-31

Completion

2020-03-31

Drugs

Indications